Albumin-based formononetin nanomedicines for lung injury and fibrosis therapy via blocking macrophage pyroptosis

[1]  T. Tian,et al.  A dynamic DNA tetrahedron framework for active targeting , 2023, Nature Protocols.

[2]  Yuxin Zhang,et al.  Albumin-Coated Framework Nucleic Acids as Bionic Delivery System for Triple-Negative Breast Cancer Therapy. , 2022, ACS applied materials & interfaces.

[3]  Yanjing Li,et al.  Prospects and challenges of dynamic DNA nanostructures in biomedical applications , 2022, Bone Research.

[4]  J. Lieberman,et al.  FcγR-mediated SARS-CoV-2 infection of monocytes activates inflammation , 2022, Nature.

[5]  Songhang Li,et al.  Tetrahedral Framework Nucleic Acids Inhibit Skin Fibrosis via the Pyroptosis Pathway. , 2022, ACS applied materials & interfaces.

[6]  Yuanyi Zheng,et al.  Prussian Blue Nanozyme as a Pyroptosis Inhibitor Alleviates Neurodegeneration , 2022, Advanced materials.

[7]  Jinsong Ding,et al.  Intrinsic Radical Species Scavenging Activities of Tea Polyphenols Nanoparticles Block Pyroptosis in Endotoxin-Induced Sepsis. , 2022, ACS nano.

[8]  Y. Liu,et al.  Inhibition of gasdermin D-dependent pyroptosis attenuates the progression of silica-induced pulmonary inflammation and fibrosis , 2021, Acta pharmaceutica Sinica. B.

[9]  Q. Gong,et al.  Pyroptosis: Mechanisms and Links with Fibrosis , 2021, Cells.

[10]  S. Turvey,et al.  Nano‐Enabled Reposition of Proton Pump Inhibitors for TLR Inhibition: Toward A New Targeted Nanotherapy for Acute Lung Injury , 2021, Advanced science.

[11]  Jie Huang,et al.  pH-Triggered Aggregation of Gold Nanoparticles for Enhanced Labeling and Long-Term CT Imaging Tracking of Stem Cells in Pulmonary Fibrosis Treatment. , 2021, Small.

[12]  S. Lipton,et al.  Metformin inhibition of mitochondrial ATP and DNA synthesis abrogates NLRP3 inflammasome activation and pulmonary inflammation , 2021, Immunity.

[13]  S. Gong,et al.  Monocarboxylate Transporter 4 Triggered Cell Pyroptosis to Aggravate Intestinal Inflammation in Inflammatory Bowel Disease , 2021, Frontiers in Immunology.

[14]  Nicola Clementi,et al.  Viral Respiratory Pathogens and Lung Injury , 2021, Clinical microbiology reviews.

[15]  Huaiyong Chen,et al.  Macrophages in Lung Injury, Repair, and Fibrosis , 2021, Cells.

[16]  Jingcheng Dong,et al.  Formononetin Attenuates Airway Inflammation and Oxidative Stress in Murine Allergic Asthma , 2020, Frontiers in Pharmacology.

[17]  P. Couvreur,et al.  Advanced nanomedicines for the treatment of inflammatory diseases , 2020, Advanced Drug Delivery Reviews.

[18]  P. Anand.  Lipids, inflammasomes, metabolism, and disease , 2020, Immunological reviews.

[19]  Lei Xing,et al.  Monocyte-derived multipotent cell delivered programmed therapeutics to reverse idiopathic pulmonary fibrosis , 2020, Science Advances.

[20]  Liu Wang,et al.  Immunity-and-matrix-regulatory cells derived from human embryonic stem cells safely and effectively treat mouse lung injury and fibrosis , 2020, bioRxiv.

[21]  Xinxia Peng,et al.  Inhalation of lung spheroid cell secretome and exosomes promotes lung repair in pulmonary fibrosis , 2020, Nature Communications.

[22]  Fei-Fei Liu,et al.  Targeting metabolic dysregulation for fibrosis therapy , 2019, Nature Reviews Drug Discovery.

[23]  N. Bottini,et al.  Secreted Protein Acidic and Rich in Cysteine Mediated Biomimetic Delivery of Methotrexate by Albumin-Based Nanomedicines for Rheumatoid Arthritis Therapy. , 2019, ACS nano.

[24]  P. Vandenabeele,et al.  The molecular machinery of regulated cell death , 2019, Cell Research.

[25]  J. Vince,et al.  Pyroptosis versus necroptosis: similarities, differences, and crosstalk , 2018, Cell Death & Differentiation.

[26]  S. Newman.  Delivering drugs to the lungs: The history of repurposing in the treatment of respiratory diseases. , 2018, Advanced drug delivery reviews.

[27]  D. Lederer,et al.  Idiopathic Pulmonary Fibrosis. , 2018, The New England journal of medicine.

[28]  C. Duvall,et al.  Harnessing albumin as a carrier for cancer therapies , 2018, Advanced drug delivery reviews.

[29]  Xu Wu,et al.  Pharmacokinetics and Bioavailability of the Isoflavones Formononetin and Ononin and Their in Vitro Absorption in Ussing Chamber and Caco-2 Cell Models. , 2018, Journal of agricultural and food chemistry.

[30]  Yanbing Ding,et al.  Formononetin Administration Ameliorates Dextran Sulfate Sodium-Induced Acute Colitis by Inhibiting NLRP3 Inflammasome Signaling Pathway , 2018, Mediators of inflammation.

[31]  Mark G. Jones,et al.  Idiopathic pulmonary fibrosis , 2017, The Lancet.

[32]  M. Mino‐Kenudson,et al.  Type I collagen–targeted PET probe for pulmonary fibrosis detection and staging in preclinical models , 2017, Science Translational Medicine.

[33]  Amit Kumar Srivastava,et al.  Hydroxyproline: A Potential Biochemical Marker and Its Role in the Pathogenesis of Different Diseases. , 2016, Current protein & peptide science.

[34]  Yi Wang,et al.  Pyroptosis is driven by non-selective gasdermin-D pore and its morphology is different from MLKL channel-mediated necroptosis , 2016, Cell Research.

[35]  F. Ossendorp,et al.  Combinatorial prospects of nano-targeted chemoimmunotherapy. , 2016, Biomaterials.

[36]  N. Siafakas,et al.  NLRP3 inflammasome expression in idiopathic pulmonary fibrosis and rheumatoid lung , 2016, European Respiratory Journal.

[37]  Jianfeng Zeng,et al.  A Self‐Assembled Albumin‐Based Nanoprobe for In Vivo Ratiometric Photoacoustic pH Imaging , 2015, Advanced materials.

[38]  Alexander Pautsch,et al.  Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis , 2015, European Respiratory Journal.

[39]  A. Wree,et al.  NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice , 2014, Hepatology.

[40]  T. Wynn,et al.  Mechanisms of fibrosis: therapeutic translation for fibrotic disease , 2012, Nature Medicine.

[41]  S. Young,et al.  Linking lipid metabolism to the innate immune response in macrophages through sterol regulatory element binding protein-1a. , 2011, Cell metabolism.

[42]  R. Schneiter,et al.  Lipid signalling in disease , 2008, Nature Reviews Molecular Cell Biology.

[43]  D. Warburton,et al.  The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis? , 2008, The international journal of biochemistry & cell biology.

[44]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[45]  Diane P. Martin,et al.  Incidence and outcomes of acute lung injury. , 2005, The New England journal of medicine.

[46]  Gary R. Grotendorst,et al.  Combinatorial signaling pathways determine fibroblast proliferation and myofibroblast differentiation , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[47]  R. Savani,et al.  Bleomycin-induced pulmonary injury in mice deficient in SPARC. , 2000, American journal of physiology. Lung cellular and molecular physiology.

[48]  P. Bornstein,et al.  Diversity of Function Is Inherent in Matricellular Proteins: an Appraisal of Thrombospondin I , 1995 .

[49]  J M Simpson,et al.  Simple method of estimating severity of pulmonary fibrosis on a numerical scale. , 1988, Journal of clinical pathology.

[50]  R. Crystal,et al.  Bleomycin-induced interstitial pulmonary disease in the nude, athymic mouse. , 2015, The American review of respiratory disease.